STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB) has presented efficacy data for MIV-701 in a preclinical osteoporosis model at the ongoing conference of the American Society for Bone and Mineral Research in Hawaii. The results demonstrate that administration of MIV-701 in this preclinical disease model significantly reduces osteoclast cell activity via inhibition of the enzyme cathepsin K. An increase in osteoclast activity leads to bone degradation and consequently osteoporosis. The activity of MIV-701 is reversible (i.e. ceases when administration no longer is continued), which is a big therapeutic advantage over other treatment regimes such as the bisphosphonates which are the conventional form of treatment today.
